Zacks: Brokerages Expect Theravance Biopharma Inc (TBPH) to Post -$1.18 Earnings Per Share

Equities research analysts predict that Theravance Biopharma Inc (NASDAQ:TBPH) will report earnings of ($1.18) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Theravance Biopharma’s earnings. The lowest EPS estimate is ($1.25) and the highest is ($1.06). Theravance Biopharma reported earnings of ($1.22) per share in the same quarter last year, which would indicate a positive year over year growth rate of 3.3%. The firm is expected to issue its next quarterly earnings results on Tuesday, May 14th.

On average, analysts expect that Theravance Biopharma will report full-year earnings of ($4.66) per share for the current year, with EPS estimates ranging from ($5.20) to ($3.47). For the next year, analysts anticipate that the business will post earnings of ($4.63) per share, with EPS estimates ranging from ($6.10) to ($3.35). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Theravance Biopharma.

Several brokerages recently issued reports on TBPH. Cantor Fitzgerald reiterated a “buy” rating and issued a $55.00 price target on shares of Theravance Biopharma in a research note on Tuesday, February 26th. Zacks Investment Research cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday. BidaskClub cut Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, March 9th. Finally, ValuEngine cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Tuesday, January 22nd. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $43.40.

In other Theravance Biopharma news, SVP Sharathchandra S. Hegde sold 9,033 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $24.71, for a total transaction of $223,205.43. Following the completion of the transaction, the senior vice president now directly owns 270,134 shares in the company, valued at $6,675,011.14. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.90% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in TBPH. Norges Bank acquired a new position in Theravance Biopharma during the fourth quarter valued at approximately $22,422,000. Candriam Luxembourg S.C.A. acquired a new position in Theravance Biopharma during the third quarter valued at approximately $8,321,000. Vanguard Group Inc raised its position in Theravance Biopharma by 3.6% during the third quarter. Vanguard Group Inc now owns 3,672,030 shares of the biopharmaceutical company’s stock valued at $119,965,000 after purchasing an additional 126,135 shares in the last quarter. Vanguard Group Inc. raised its position in Theravance Biopharma by 3.6% during the third quarter. Vanguard Group Inc. now owns 3,672,030 shares of the biopharmaceutical company’s stock valued at $119,965,000 after purchasing an additional 126,135 shares in the last quarter. Finally, First Trust Advisors LP acquired a new position in Theravance Biopharma during the fourth quarter valued at approximately $2,243,000. Institutional investors and hedge funds own 84.42% of the company’s stock.

Shares of TBPH stock opened at $22.95 on Tuesday. The company has a debt-to-equity ratio of 6.52, a current ratio of 5.41 and a quick ratio of 5.41. The company has a market capitalization of $1.28 billion, a P/E ratio of -5.75 and a beta of 1.69. Theravance Biopharma has a 1 year low of $21.04 and a 1 year high of $35.48.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria.

See Also: Dividend Aristocrat Index

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.